Real-World Experience Transplanting Hepatitis C Seropositive Livers into Seronegative Recipients

High hepatitis C cure rates in recipients were observed, but so was some difficulty in obtaining expensive antiviral treatment.

Aiming to address the critical shortage of organs, the strategy of expected transmission of hepatitis C virus (HCV) from organ donors to recipients with subsequent use of direct-acting antivirals (DAAs) to cure recipients has been described in heart, lung, and kidney recipients (NEJM JW Infect Dis Jun 2019 and N Engl J Med 2019; 380:1606; NEJM JW Infect Dis Oct 2018 and Ann Intern Med 2018; 169:273). Now, investigators have retrospectively reviewed data on transplantation of livers from HCV-seropositive donors into 26 HCV-seronegative recipients at one center from January 1, 2017, to August 31, 2019. Twenty of the donors were nucleic acid (NAT) positive; all 20 recipients of these livers developed HCV viremia. Among the recipients of the 5 …

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Real-World Experience Transplanting Hepatitis C Seropositive Livers into Seronegative Recipients

Topics

Reviewing Author